- Home
- LYEL vs DPG Comparison
LYEL vs DPG Comparison
Compare LYEL & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$23.20
Company Overview
Basic Information| Metric | LYEL | DPG |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 535.3M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | LYEL | DPG |
|---|---|---|
| Price | $23.20 | $14.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $30.60 | N/A |
| AVG Volume (30 Days) | ★ 79.7K | 78.5K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16,285.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $11.60 |
| 52 Week High | $45.00 | $15.15 |
Technical Indicators
Market Signals| Indicator | LYEL | DPG |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 56.11 |
| Support Level | $21.27 | $14.04 |
| Resistance Level | $27.30 | $14.81 |
| Average True Range (ATR) | 1.70 | 0.25 |
| MACD | 0.53 | 0.02 |
| Stochastic Oscillator | 75.83 | 57.63 |
Price Performance
Historical Comparison LYEL
DPG
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.